Product Description
XL102 is a potent, selective and orally bioavailable covalent inhibitor of CDK7, which is an important regulator of the cellular transcriptional and cell cycle machinery.
Mechanisms of Action: CDK7 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Exelixis
Company Location: ALAMEDA CA 94502
Company CEO: Michael M. Morrissey
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Prostate Cancer|Ovarian Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QUARTZ-101 | P1 |
Terminated |
Prostate Cancer|Triple Negative Breast Cancer|Ovarian Cancer |
2024-05-02 |
50% |